APDN - Applied DNA Corp Company Projected Revenue

Official company branding of Applied DNA (APDN)

Leadership in synthetic biology and PCR amplification provides Applied DNA Sciences (APDN) with a powerful cash flow. The firm's projected sales volume confirms this trend, where the 0.00 level represents the current value. Currently, growth is supported by contract manufacturing and diagnostics, while patent protection and ties to the defense sector create significant barriers to entry for competitors, ensuring business sustainability.

APDN - adnas.com Projected Sales Volume over the range 07/04/2022 - 10/07/2025

Analytical breakdowns and data insights for company Applied DNA (APDN)

- stock quotes and analyst forecast:
Fundamental company analysis:Applied DNA Sciences Inc
Signature product of Applied DNA Sciences Inc

This metric measures the kinetic energy of an asset's market revaluation through new order dynamics. Investors assess the sustainability of the upward revenue momentum to determine a timely entry point. Analyzing the company's projected sales volumes allows for the identification of critical risk threshold breaches. For Applied DNA Sciences (APDN), this reflects the efficiency of outsourcing the production of reagents and tests. The optimization of cloud capacities directly impacts the growth rate of this indicator.

Main competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Company Future Sales Volume 10x Genomics TXG|Company Projected Revenue Intellia Therapeutics NTLA|Company Projected Revenue Volume STOK (Stoke Therapeutics, Inc.)|BLFS - Company Projected Revenue|Company Expected Sales Volume Wave Pharma|mazetx.com (MAZE) - Company Projected Revenue|SION - Company Future Sales|PRME (Prime Medicine Inc) - Projected Sales Volume|Taysha Gene Therapies, Inc. - Company Expected Revenue|Projected Sales Volume QURE|MGTX: Company Expected Revenue|Company Projected Revenue REGENXBIO RGNX|SLDB: Company Revenue Forecast|OCGN: Company Future Sales Volume|PACB - Projected Sales Volume|BNTC (Benitec Corp) - Company Future Sales Volume|Company Sales Forecast Design Corp DSGN|Company Projected Revenue Rocket Pharmaceuticals|Projected Sales Volume 4D Molecular Therapeutics, Inc.|Company Projected Revenue Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Company Future Revenue|Projected Sales Volume EDIT (Editas Medicine, Inc.)|Projected Sales Volume Silence Therapeutics Corp SLN|PRQR - Company Projected Revenue|Company Future Sales Codexis Inc CDXS|SGMO: Projected Sales Volume|Company Revenue Forecast NAUT|Company Projected Revenue metagenomi.co|Projected Sales Volume Precision BioSciences Inc.|Projected Sales Volume GBIO|Boundless Bio, Inc. - Company Revenue Forecast|Projected Sales Volume XCUR (Exicure, Inc.)|Company Future Sales Imunon, Inc. (IMNN)|PHIO - Company Projected Revenue|Company Future Revenue MBIO (mustangbio.com)|RNAZ: Projected Sales Volume|Company Revenue Forecast BNGO|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume